353 related articles for article (PubMed ID: 32438856)
1. Could the human papillomavirus vaccine prevent recurrence of ano-genital warts?: a systematic review and meta-analysis.
Husein-ElAhmed H
Int J STD AIDS; 2020 Jun; 31(7):606-612. PubMed ID: 32438856
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
Broomall EM; Reynolds SM; Jacobson RM
Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
[TBL] [Abstract][Full Text] [Related]
3. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.
Pitisuttithum P; Velicer C; Luxembourg A
Expert Rev Vaccines; 2015; 14(11):1405-19. PubMed ID: 26366475
[TBL] [Abstract][Full Text] [Related]
4. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.
Marty R; Roze S; Bresse X; Largeron N; Smith-Palmer J
BMC Cancer; 2013 Jan; 13():10. PubMed ID: 23298365
[TBL] [Abstract][Full Text] [Related]
5. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
6. From the monovalent to the nine-valent HPV vaccine.
Pils S; Joura EA
Clin Microbiol Infect; 2015 Sep; 21(9):827-33. PubMed ID: 25980355
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus and genital cancer.
Rapose A
Indian J Dermatol Venereol Leprol; 2009; 75(3):236-43; quiz 243-4. PubMed ID: 19439875
[TBL] [Abstract][Full Text] [Related]
8. Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.
Park IU; Introcaso C; Dunne EF
Clin Infect Dis; 2015 Dec; 61 Suppl 8():S849-55. PubMed ID: 26602622
[TBL] [Abstract][Full Text] [Related]
9. [Human Papillomavirus infection and vaccination: knowledge and attitudes of Italian general practitioners].
Signorelli C; Odone A; Pezzetti F; Spagnoli F; Visciarelli S; Ferrari A; Camia P; Latini C; Ciorba V; Agodi A; Barchitta M; Scotti S; Misericordia P; Pasquarella C
Epidemiol Prev; 2014; 38(6 Suppl 2):88-92. PubMed ID: 25759351
[TBL] [Abstract][Full Text] [Related]
10. Human Papillomavirus Vaccination: ACOG Committee Opinion, Number 809.
American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group
Obstet Gynecol; 2020 Aug; 136(2):e15-e21. PubMed ID: 32732766
[TBL] [Abstract][Full Text] [Related]
11. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
Kim JJ
Lancet Infect Dis; 2010 Dec; 10(12):845-52. PubMed ID: 21051295
[TBL] [Abstract][Full Text] [Related]
12. Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007-2018).
Cocchio S; Prandi GM; Furlan P; Bertoncello C; Fonzo M; Saia M; Baldovin T; Baldo V
BMC Infect Dis; 2020 Nov; 20(1):857. PubMed ID: 33208109
[TBL] [Abstract][Full Text] [Related]
13. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
14. A review of clinical trials of human papillomavirus prophylactic vaccines.
Schiller JT; Castellsagué X; Garland SM
Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
[TBL] [Abstract][Full Text] [Related]
15. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
McCormack PL
Drugs; 2014 Jul; 74(11):1253-83. PubMed ID: 25022951
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.
Giuliano AR; Tortolero-Luna G; Ferrer E; Burchell AN; de Sanjose S; Kjaer SK; Muñoz N; Schiffman M; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 10(0 10):K17-28. PubMed ID: 18847554
[TBL] [Abstract][Full Text] [Related]
17. 9-Valent human papillomavirus vaccine: a review of the clinical development program.
Luxembourg A; Moeller E
Expert Rev Vaccines; 2017 Nov; 16(11):1119-1139. PubMed ID: 28956458
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccine trials and tribulations: Clinical perspectives.
Handler MZ; Handler NS; Majewski S; Schwartz RA
J Am Acad Dermatol; 2015 Nov; 73(5):743-56; quiz 757-8. PubMed ID: 26475534
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
[TBL] [Abstract][Full Text] [Related]
20. Genital warts.
Steben M; Garland SM
Best Pract Res Clin Obstet Gynaecol; 2014 Oct; 28(7):1063-73. PubMed ID: 25155525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
